This Biotech Dived After The FDA Put Its Gene Therapy Study On PauseInvestors Business Daily • 11/06/19
REGENXBIO, Inc. (RGNX) CEO Kenneth Mills on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/06/19
Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector™ in AAV Gene Therapy DeliveryGlobeNewsWire • 10/30/19
Regenxbio's Wet AMD Data Is Encouraging, With Majority Of Patients Free Of Rescue InjectionsSeeking Alpha • 10/30/19
Regenxbio, Inc. (RGNX) CEO Kenneth Mills on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/08/19
Are Options Traders Betting on a Big Move in REGENXBIO (RGNX) Stock?Zacks Investment Research • 07/02/19
Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and RegenxbioThe Motley Fool • 05/24/19
Regenxbio, Inc. (RGNX) CEO Kenneth Mills on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/08/19
A Second Baby Died In A Gene Therapy Study — Slugging This Biotech StockInvestors Business Daily • 04/22/19